Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
|
19018267 |
2008 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Implications of NRAS mutations in AML: a study of 2502 patients.
|
16434492 |
2006 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
|
2278970 |
1990 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
|
3122217 |
1987 |
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
Breast adenocarcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.
|
30896620 |
2019 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |